Skip to main content
Top
Published in: Pathology & Oncology Research 4/2012

01-10-2012 | Research

The Value of the Preoperative FISH Test in Unscreened Bladder Cancer Patients with TUR Indications

Authors: S. V. Petrov, K. A. Malkhasyan, M. Yu. Ulyanin, E. F. Abdrakhmanov, R. Sh. Khasanov

Published in: Pathology & Oncology Research | Issue 4/2012

Login to get access

Abstract

Patients with bladder cancer are still requiring close follow up with frequent cystoscopies. This study aims to assess the FISH analysis, as a procedure capable of highlighting the hidden features of a tumor and helping to individualize treatment tactics. The bladder washings of 50 primary bladder cancer patients were taken prior to TURB and analyzed with the commercial FISH assay UroVysion®. All patients were divided into groups according to the maximum stage and grade of the tumor. The sensitivity of the method was 81.5 %, 91.7 % and 100 % for the Ta, T1 and T2 stage groups, respectively. For the G1, G2 and G3 groups the sensitivity was 70 %, 100 % and 100 %, respectively. In addition, the rate of detecting genetically abnormal cells was significantly higher in the T2 stage compared to the Ta and combined Ta+T1 groups, as well as in the G3 group compared to the G1 and G2 groups. The mean signal number from each chromosome insignificantly increased with the stage and grade of the tumor. The detection of <40 % genetically abnormal cells predicted the absence of muscle invasion and a G3 tumor with more then 90 % reliability. The FISH method is highly sensitive in early bladder cancer detection and is able to predict the morphological character of a tumor even before surgery.
Literature
1.
go back to reference Davydov M, Aksel E (2009) Statistics of the malignant neoplasm in Russia and CIS countries in 2007. J Blokhin RCRC RAMS 20, N3(77) Davydov M, Aksel E (2009) Statistics of the malignant neoplasm in Russia and CIS countries in 2007. J Blokhin RCRC RAMS 20, N3(77)
2.
go back to reference Matveev B, Kudashev B, Bukharkin B, Romanov V, Rubanov Yu (2000) The role of fluorescent control in improvement of surgical radicalism in superficial bladder cancer. Urology 3:22–24 Matveev B, Kudashev B, Bukharkin B, Romanov V, Rubanov Yu (2000) The role of fluorescent control in improvement of surgical radicalism in superficial bladder cancer. Urology 3:22–24
3.
go back to reference World Health Organization. World cancer report, 2003. IARC Press, Lyon, France, 2003, p 229 World Health Organization. World cancer report, 2003. IARC Press, Lyon, France, 2003, p 229
4.
5.
go back to reference Cairns P, Shaw ME, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8:1083–1085PubMed Cairns P, Shaw ME, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8:1083–1085PubMed
6.
go back to reference Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C (1995) Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87:1524–1529PubMedCrossRef Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C (1995) Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87:1524–1529PubMedCrossRef
7.
go back to reference Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W (2000) The development of a multitarget, multicolor fluorescence in Situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2:116–123PubMedCrossRef Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W (2000) The development of a multitarget, multicolor fluorescence in Situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2:116–123PubMedCrossRef
8.
go back to reference Bashkatov S, Sevankaeva A, Karyakin O, Mikhailova G, Golub E (2008) Fluorescent hybridization in situ: practical application in oncourology. Oncourology 3:9–15 Bashkatov S, Sevankaeva A, Karyakin O, Mikhailova G, Golub E (2008) Fluorescent hybridization in situ: practical application in oncourology. Oncourology 3:9–15
9.
go back to reference Vorobcova I, Vasileva Z, Shkolnik M, Timofeeva D, Odincova M, Gappoev M, Urbanskiy A (2011) The use of fluorescent in situ hybridization on the urine sediment cells for diagnostics of bladder cancer and it’s recurrence. Oncourology 1:73–78 Vorobcova I, Vasileva Z, Shkolnik M, Timofeeva D, Odincova M, Gappoev M, Urbanskiy A (2011) The use of fluorescent in situ hybridization on the urine sediment cells for diagnostics of bladder cancer and it’s recurrence. Oncourology 1:73–78
10.
go back to reference Bubendorf L, Grilli B, Sauter G et al (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116(1):79–86PubMedCrossRef Bubendorf L, Grilli B, Sauter G et al (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116(1):79–86PubMedCrossRef
11.
go back to reference Degtyar P, Neulander E, Zirkin H et al (2004) Fluorescence in situ hybridization performed on exfoliated urothelial cell in patients with transitional cell carcinomas of the bladder. Urology 63(2):398–401PubMedCrossRef Degtyar P, Neulander E, Zirkin H et al (2004) Fluorescence in situ hybridization performed on exfoliated urothelial cell in patients with transitional cell carcinomas of the bladder. Urology 63(2):398–401PubMedCrossRef
12.
go back to reference Lokeshwar VB, Habuchi T, Grossman B (2005) Bladder tumor markers beyond cytology: international consensus on bladder tumor markers. Urology 66(suppl):35–63PubMedCrossRef Lokeshwar VB, Habuchi T, Grossman B (2005) Bladder tumor markers beyond cytology: international consensus on bladder tumor markers. Urology 66(suppl):35–63PubMedCrossRef
13.
go back to reference Placer J, Espinet B, Salido M et al (2002) Clinical utility of a multiprobe FISH assay in voided urine specimens for detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42(6):547–552PubMedCrossRef Placer J, Espinet B, Salido M et al (2002) Clinical utility of a multiprobe FISH assay in voided urine specimens for detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42(6):547–552PubMedCrossRef
14.
go back to reference Sevankaev A, Lushnikov E, Karyakin O, Mikhailova G, Gorban N, Bashkatov S, Golub E, Shkavrova T, Cepenko V (2008) Clinical use of the FISH method in early detection of superficial bladder cancer. Oncourology 4:61–65 Sevankaev A, Lushnikov E, Karyakin O, Mikhailova G, Gorban N, Bashkatov S, Golub E, Shkavrova T, Cepenko V (2008) Clinical use of the FISH method in early detection of superficial bladder cancer. Oncourology 4:61–65
15.
go back to reference Richter J, Jiang F, Gorog JP et al (1997) Marker ganetic differences between atage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57:2860–2864PubMed Richter J, Jiang F, Gorog JP et al (1997) Marker ganetic differences between atage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57:2860–2864PubMed
16.
go back to reference Babayan A, Bashkatov S, Karyakin O, Teplov A, Golovashenko M, Shkarupo V, Zaletaev D, Nemcova D (2009) Molecular-genetic markers as disease course predictors in superficial bladder cancer. Oncourology 3:19–24 Babayan A, Bashkatov S, Karyakin O, Teplov A, Golovashenko M, Shkarupo V, Zaletaev D, Nemcova D (2009) Molecular-genetic markers as disease course predictors in superficial bladder cancer. Oncourology 3:19–24
17.
go back to reference Olumi AF, Tsai YC, Nichols PW et al (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7081–7083PubMed Olumi AF, Tsai YC, Nichols PW et al (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7081–7083PubMed
18.
go back to reference Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997–1008PubMedCrossRef Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997–1008PubMedCrossRef
19.
go back to reference Brauers A, Buettner R, Jakse G (2001) Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 165(3):808–810PubMedCrossRef Brauers A, Buettner R, Jakse G (2001) Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 165(3):808–810PubMedCrossRef
20.
go back to reference Dutta SC, Smith JA Jr, Shappell SB et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493PubMedCrossRef Dutta SC, Smith JA Jr, Shappell SB et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493PubMedCrossRef
21.
go back to reference Herr HW, Donat MS (2008) Quality control in transurethral resection of bladder tumors. BJU Int 102:1242–1246PubMedCrossRef Herr HW, Donat MS (2008) Quality control in transurethral resection of bladder tumors. BJU Int 102:1242–1246PubMedCrossRef
22.
go back to reference Jakse G, Algaba MPU, Osterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45(5):539–546PubMedCrossRef Jakse G, Algaba MPU, Osterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45(5):539–546PubMedCrossRef
23.
go back to reference Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76PubMedCrossRef Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76PubMedCrossRef
24.
go back to reference Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM (2011) Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Pathol 18(1):79–89PubMedCrossRef Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM (2011) Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Pathol 18(1):79–89PubMedCrossRef
25.
go back to reference Magi-Galluzzi C, Epstein JI (2004) Urothelial papilloma of the bladder: a review of 34 de novo cases. Am J Surg Pathol 28(12):1615–1620PubMedCrossRef Magi-Galluzzi C, Epstein JI (2004) Urothelial papilloma of the bladder: a review of 34 de novo cases. Am J Surg Pathol 28(12):1615–1620PubMedCrossRef
Metadata
Title
The Value of the Preoperative FISH Test in Unscreened Bladder Cancer Patients with TUR Indications
Authors
S. V. Petrov
K. A. Malkhasyan
M. Yu. Ulyanin
E. F. Abdrakhmanov
R. Sh. Khasanov
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9544-6

Other articles of this Issue 4/2012

Pathology & Oncology Research 4/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine